Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment save search
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2023-02-08 (Crawled : 14:20) - globenewswire.com
SAVA | $29.84 -0.13% 750K
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
treatment sciences disease for alzheimer’s update
First Citizens Bank Provides $31.2 Million for Acquisition of Cancer Treatment Center in Columbia, South Carolina
Published: 2023-02-08 (Crawled : 14:00) - prnewswire.com
FCNCA | $787.82 -0.45% 13K
|
Finance
|
| O: -0.25%
H: 0.0%
C: 0.0%
treatment acquisition for cancer
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
Published: 2023-02-08 (Crawled : 13:20) - biospace.com/
LCTX | $1.405 -2.43% 88K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment for program update
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Published: 2023-02-08 (Crawled : 13:00) - prnewswire.com
ANVS | $19.37 2.38% 27K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
treatment disease for parkinson's buntanetap trial approval study
Gerresheimer and Corning announce joint venture to meet growing demand for Velocity® Vials, accelerating the delivery of lifesaving treatments
Published: 2023-02-08 (Crawled : 10:00) - prnewswire.com
GLW | $35.04 -0.43% 1.2M
|
Electronic Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
velocity for growing corning
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers – Molecular Cancer Therapeutics – AACR Journals
Published: 2023-02-07 (Crawled : 00:00) - sutrobio.com
STRO | $6.83 -2.43% 260K
|
Health Technology
|
| O: 2.79%
H: 0.0%
C: 0.0%
stro-002 treatment for therapeutics molecular cancer aacr journals
The IVF Treatment Process – A Step by Step Video Guide
Published: 2023-02-07 (Crawled : 18:00) - progyny.com
PGNY M | $31.98 -0.09% 240K
|
Commercial Services
|
| O: -7.2%
H: 0.0%
C: 0.0%
treatment
Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
KPRX | $5.64 23.96% 3.6M
|
Manufacturing
|
| O: 64.94%
H: 0.0%
C: 0.0%
kio-101 treatment pharmaceuticals drug for ocular approval presentation study
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-02-07 (Crawled : 14:00) - prnewswire.com
RETA | $50.3 2.17% 150K
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
CNSP | $2.16 3.2K
|
Health Technology
|
| O: -1.7%
H: 0.0%
C: 0.0%
treatment ongoing pharmaceuticals global for trial berubicin
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
ALDX | $6.78 0.15% 150K
|
Health Technology
|
| O: 8.04%
H: 0.0%
C: 0.0%
treatment fda drug disease for eye application therapeutics reproxalap
NexPoint Residential Trust Announces 2022 Dividend Income Tax Treatment
Published: 2023-02-06 (Crawled : 00:00) - prnewswire.com
NXRT | $51.18 -0.08% 24K
|
Finance
|
| O: -0.4%
H: 0.0%
C: 0.0%
treatment dividend trust
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma
Published: 2023-02-06 (Crawled : 14:20) - ir.pulmatrix.com
PULM | $3.8666 16K
|
Health Technology
|
| O: -3.46%
H: 3.44%
C: 1.42%
pur1900 treatment for study phase 2b
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Published: 2023-02-06 (Crawled : 13:20) - isoray.com
ISR | $0.4078 -2.91% 190K
|
Health Technology
|
| O: 2.5%
H: 7.32%
C: 3.41%
treatment molecular
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Discuss DERMAdoctor’s Eczema Treatment on Two QVC® Shows on February 7
Published: 2023-02-06 (Crawled : 13:00) - biospace.com/
NBY | $2.2 -5.58% 8.1K
|
Health Technology
|
| O: -3.14%
H: 0.0%
C: -0.81%
qvc treatment pharmaceuticals eczema
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies
Published: 2023-02-06 (Crawled : 13:00) - prnewswire.com
ATNM | $12.51 -0.4% 66K
|
Health Technology
|
| O: 3.17%
H: 0.0%
C: 0.0%
treatment research for leukemia agreement cancer
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Published: 2023-02-06 (Crawled : 13:00) - globenewswire.com
CNTX | $0.9688 100K
|
Health Technology
|
| O: -8.02%
H: 13.11%
C: 5.44%
treatment ona-xr for trial therapeutics cancer phase 2
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:20) - biospace.com/
SAGE | $45.81 -1.63% 56K
|
Health Technology
|
| O: -0.19%
H: 6.75%
C: 3.25%
BIIB A | $288.03 -1.17% 160K
|
Health Technology
|
| O: -1.7%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression
Myelofibrosis Treatment Market to Reach $1.16 Billion, Globally, by 2031 at 4.0% CAGR: Allied Market Research
Published: 2023-02-06 (Crawled : 12:00) - prnewswire.com
GSK | $36.375 0.57% 1.2M
|
Health Technology
|
| O: 0.14%
H: 0.24%
C: -0.17%
BMY A | $73.49 -1.38% 3.4M
|
Health Technology
|
| O: 1.65%
H: 0.98%
C: 0.11%
AMRX | $2.66 -1.48% 500K
|
Health Technology
|
| O: 4.97%
H: 6.58%
C: 4.53%
ABBV | $146.1 0.66% 1.6M
|
Health Technology
|
| O: -0.42%
H: 0.4%
C: -0.49%
INCY | $80.84 -0.15% 630K
|
Health Technology
|
| O: -0.62%
H: 0.0%
C: 0.0%
GLTO | $2.74 -4.2% 74K
|
Health Technology
|
| O: -0.74%
H: 3.36%
C: 1.12%
treatment research market
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Published: 2023-02-06 (Crawled : 12:00) - globenewswire.com
SAGE | $45.81 -1.63% 56K
|
Health Technology
|
| O: -0.19%
H: 6.75%
C: 3.25%
BIIB A | $288.03 -1.17% 160K
|
Health Technology
|
| O: -1.7%
H: 2.52%
C: 1.12%
treatment fda drug application grants therapeutics review depression
Teleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate
Published: 2023-02-06 (Crawled : 12:00) - globenewswire.com
TFX | $254.335 -1.23% 29K
|
Health Technology
|
| O: -1.78%
H: 0.0%
C: 0.0%
urolift treatment system for
Gainers vs Losers
| 52% | 48% |
Top 10 Gainers
DGLY | $5.4 1712.08% 73K
|
Electronic Technology
CELZ | $1.08 108.78% 91M
|
GFAI | $0.4665 36.6% 44M
|
BJDX | $0.619 32.66% 2M
|
MSGM P | $16.48 25.04% 4.6M
|
PRFX | $0.625 25.0% 12M
|
Health Technology
KPRX | $5.64 23.96% 3.6M
|
Manufacturing
BBLG | $0.3799 20.76% 650K
|
n/a
NEWR A | $76.89 19.06% 2.2M
|
Technology Services
THCH | $5.0 19.05% 370K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.